New Data for Genentech’s Columvi and Lunsumio at ASH Back Continued Benefit in Lymphoma

 

• Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas
• New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies

https://www.biospace.com/article/releases/new-data-for-genentech-s-columvi-and-lunsumio-presented-at-ash-2023-support-continued-benefit-for-people-with-lymphoma/